NCT05555862View on ClinicalTrials.gov

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 28, 2026

Study Completion Date

December 31, 2026

Conditions
Anal High Grade Squamous Intraepithelial LesionAnal Precancerous ConditionAIN 2/3HPV InfectionAnal DysplasiaHPV Disease
Interventions
DRUG

Artesunate

artesunate formulated as intra-anal suppositories

DRUG

Placebo

placebo intra-anal suppository

Trial Locations (2)

10011

Laser Surgery Care, New York

60614

Anal Dysplasia Clinic MidWest, Chicago

Sponsors
All Listed Sponsors
collaborator

Amarex CRO

UNKNOWN

collaborator

University of California, San Francisco

OTHER

collaborator

Anal Dysplasia Clinic MidWest

UNKNOWN

collaborator

Laser Surgery Care

OTHER

lead

Frantz Viral Therapeutics, LLC

INDUSTRY

NCT05555862 - Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL | Biotech Hunter | Biotech Hunter